EUVIMEDEUVIMED entdecken
Open Access

Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes

Julie M Paik, Helen Tesfaye, Gary C Curhan, Heidi Zakoul, Deborah J Wexler, Elisabetta Patorno

JAMA Internal Medicine · 01.03.2024 · 184 (3) · 265

DOI: 10.1001/jamainternmed.2023.7660 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Internal Medicine, erschienen am 01.03.2024. Verfasst von Julie M Paik und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Nephrolithiasis, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NIA NIH HHS, FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Type 2 diabetes (T2D) is associated with an increased risk of kidney stones. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) might lower the risk of nephrolithiasis by altering urine composition. However, no studies have investigated the association between SGLT2i use and nephrolithiasis risk in patients receiving routine care in the US.

Objective

To investigate the association between SGLT2i use and nephrolithiasis risk in clinical practice. Design, Setting, and Participants This new-user, active comparator cohort study used data from commercially insured adults (aged ≥18 years) with T2D who initiated treatment with SGLT2is, glucagon-like peptide 1 receptor agonists (GLP-1RAs), or dipeptidyl peptidase 4 inhibitors (DPP4is) between April 1, 2013, and December 31, 2020. The data were analyzed from July 2021 through June 2023. Exposure New initiation of an SGLT2i, GLP-1RA, or DPP4i. Main Outcomes and Measures The primary outcome was nephrolithiasis diagnosed by International Classification of Diseases codes in the inpatient or outpatient setting. New SGLT2i users were 1:1 propensity score matched to new users of a GLP-1RA or DPP4i in pairwise comparisons. Incidence rates, rate differences (RDs), and estimated hazard ratios (HRs) with 95% CIs were calculated.

Results

After 1:1 propensity score matching, a total of 716 406 adults with T2D (358 203 pairs) initiating an SGLT2i or a GLP-1RA (mean [SD] age, 61.4 [9.7] years for both groups; 51.4% vs 51.2% female; 48.6% vs 48.5% male) and 662 056 adults (331 028 pairs) initiating an SGLT2i or a DPP4i (mean [SD] age, 61.8 [9.3] vs 61.7 [10.1] years; 47.4% vs 47.3% female; 52.6% vs 52.7% male) were included. Over a median follow-up of 192 (IQR, 88-409) days, the risk of nephrolithiasis was lower in patients initiating an SGLT2i than among those initiating a GLP-1RA (14.9 vs 21.3 events per 1000 person-years; HR, 0.69 [95% CI, 0.67-0.72]; RD, −6.4 [95% CI, −7.1 to −5.7]) or a DPP4i (14.6 vs 19.9 events per 1000 person-years; HR, 0.74 [95% CI, 0.71-0.77]; RD, −5.3 [95% CI, −6.0 to −4.6]). The association between SGLT2i use and nephrolithiasis risk was similar by sex, race and ethnicity, history of chronic kidney disease, and obesity. The magnitude of the risk reduction with SGLT2i use was larger among adults aged younger than 70 years vs aged 70 years or older (HR, 0.85 [95% CI, 0.79-0.91]; RD, −3.46 [95% CI, −4.87 to −2.05] per 1000 person-years; P for interaction <.001). Conclusions and Relevance These findings suggest that in adults with T2D, SGLT2i use may lower the risk of nephrolithiasis compared with GLP-1RAs or DPP4is and could help to inform decision-making when prescribing glucose-lowering agents for patients who may be at risk for developing nephrolithiasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2NephrolithiasisDipeptidyl-Peptidase IV InhibitorsAdultHumansFemaleMaleAdolescentMiddle AgedCohort StudiesInpatientsGlucoseSodiumHypoglycemic AgentsGlucagon-Like Peptide-1 ReceptorRetrospective Studies

Substanzen

Dipeptidyl-Peptidase IV InhibitorsGlucoseSodiumHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
  • Division of Renal (Kidney) Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
  • New England Geriatric Research, Education and Clinical Center, VA Boston Healthcare System, Boston, Massachusetts.
  • Harvard Medical School, Boston, Massachusetts.
  • Diabetes Center, Massachusetts General Hospital, Boston, Massachusetts.

Förderung

  • NIAMS NIH HHS
  • NIA NIH HHS
  • FDA HHS

Zitieren

APA

Paik, J. M., Tesfaye, H., Curhan, G. C., Zakoul, H., Wexler, D. J., & Patorno, E. (2024). Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes. JAMA Internal Medicine, 184(3), 265. https://doi.org/10.1001/jamainternmed.2023.7660

Vancouver

Paik JM, Tesfaye H, Curhan GC, Zakoul H, Wexler DJ, Patorno E. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes. JAMA Internal Medicine. 2024;184(3):265. doi:10.1001/jamainternmed.2023.7660

BibTeX
@article{Paik2024,
  author = {Paik, Julie M and Tesfaye, Helen and Curhan, Gary C and Zakoul, Heidi and Wexler, Deborah J and Patorno, Elisabetta},
  title = {Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes},
  journal = {JAMA Internal Medicine},
  year = {2024},
  volume = {184},
  number = {3},
  pages = {265},
  doi = {10.1001/jamainternmed.2023.7660}
}
Kostenlos starten →